| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2018-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14d82a9ed80b46ce1b73b7914f54350a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_506e7b86d62bf4ef38d5de470831c3bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3a348cb487490dc682145e07f0bf780
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a22aa30ef1690a17c0d83c60a9f9a45 |
| publicationDate |
2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112019017466-A2 |
| titleOfInvention |
USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIBLE FOR TREATMENT WITH A PRMT5 INHIBITOR |
| abstract |
the present invention relates to a method of identifying a patient that is likely to be responsive to treatment with an arginine n-methyltransferase 5 (prmt5) inhibitor comprising: evaluating a biological sample from the patient for the presence of a change spliceosome, in which the presence of any said change indicates a higher probability that said patient will be responsive to treatment with said prmt5 inhibitor than in the absence of any said mutation or change. |
| priorityDate |
2017-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |